Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 66 Pages
|Lebrikizumab(氣喘治療藥):市場預測與分析 Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023|
|出版日期: 2014年08月31日||內容資訊: 英文 66 Pages||
GlobalData has released its new PharmaPoint Drug Evaluation report, "Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023". The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Roche's lebrikizumab is under development for the treatment of patients with moderate to severe asthma who respond poorly to medium or high doses of ICSs. Lebrikizumab is a first-in-class immunoglobulin G4 (IgG4) humanized mAb that specifically binds to and inhibits the activity of IL-13. IL-13 is a pleiotropic cytokine of the Th2 cell response that contributes to asthma pathogenesis via increased chemokine secretion and mucus hyperexcretion, increased cholinergic-induced contractions, and smooth muscle proliferation (Khurana Hershey, 2003). Clinical studies have correlated the presence of elevated periostin levels with the increased efficacy of lebrikizumab.